Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fibrocell's Wrinkle Drug Underlines Challenges Of Seeking Aesthetic Claims

Executive Summary

An FDA advisory committee made very clear that the bar should be much higher for novel products proposed for aesthetic indications than for drugs to treat diseases during the Oct. 9 review of Fibrocell Science's wrinkle therapy Laviv (azfibrocel-T)

You may also be interested in...



Missing Mechanism Of Action Dogged Laviv Review

Absence of data about what happens under the surface of the skin when the cell therapy for wrinkles is injected raised safety concerns.

Fibrocell Provides Final Data To Resolve FDA Concerns On Its Autologous Stem Cell Therapy For Facial Wrinkles

The biotech hopes next to advance its technology into treatment of acne scarring; the laViv PDUFA date is June 22.

Stem Cell Therapies Walk A Risky Regulatory Road

As the most advanced stem cell therapies, known collectively these days as "regenerative medicine," edge into the clinic, much about the field remains unresolved – including basic regulatory questions and whether the therapies, which hope to restore circulation to ischemic tissue or function to damaged nerves, for example, will even work in humans.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel